Circio invites to a company update on Wednesday 17 April 2024

Oslo, Norway, 9 April 2024 – Circio Holding ASA (OSE: CRNA): Circio’s management invites to a company update hosted by Redeye on Wednesday 17 April at 8am CEST. In the webcast, CEO Erik Digman Wiklund will provide an overview of the latest circVec circular RNA platform in vivo data and the focused gene therapy R&D strategy, and CFO Lubor Gaal will present unaudited financial results for 2023. Following the presentation, there will be a Q&A session with Redeye´s equity research analyst Richard Ramanius.

Date: Wednesday 17 April 2024
Time: 8:00am CEST
Watch: Available on demand via and (link provided on the day)
Presenters:  Dr. Erik Digman Wiklund, Chief Executive Officer (CEO)
Dr. Lubor Gaal, Chief Financial Officer (CFO)


Questions can be submitted in advance until 18:00 CEST on Monday 15 April in English, Norwegian and Swedish, and will be addressed in the respective language.

Submit your questions to CFO Lubor Gaal by email:

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536

Renate Birkeli, Investor Relations
Phone: +47 922 61 624

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for rare disease, vaccines, and cancer. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed for many purposes. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in three clinical trials: RAS-mutated pancreatic cancer and lung and non-resectable pancreatic cancer in US, and multiple myeloma in Norway. These studies are being run through academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.